461 related articles for article (PubMed ID: 30957864)
1. Patent foramen ovale closure for secondary stroke prevention.
Alkhouli M; Sievert H; Holmes DR
Eur Heart J; 2019 Jul; 40(28):2339-2350. PubMed ID: 30957864
[TBL] [Abstract][Full Text] [Related]
2. Patent Foramen Ovale: Stroke and Device Closure.
Suradi HS; Hijazi ZM
Cardiol Clin; 2016 May; 34(2):231-40. PubMed ID: 27150171
[TBL] [Abstract][Full Text] [Related]
3. Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements.
Elzanaty AM; Patel N; Sabbagh E; Eltahawy EA
Curr Med Res Opin; 2021 Mar; 37(3):377-384. PubMed ID: 33460329
[TBL] [Abstract][Full Text] [Related]
4. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
5. Transcatheter Closure of Patent Foramen Ovale: Devices and Technique.
Price MJ
Interv Cardiol Clin; 2017 Oct; 6(4):555-567. PubMed ID: 28886846
[TBL] [Abstract][Full Text] [Related]
6. Current Dataset for Patent Foramen Ovale Closure in Cryptogenic Stroke: Randomized Clinical Trials and Observational Studies.
Odunukan OW; Price MJ
Interv Cardiol Clin; 2017 Oct; 6(4):525-538. PubMed ID: 28886843
[TBL] [Abstract][Full Text] [Related]
7. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
Wiktor DM; Carroll JD
Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
[TBL] [Abstract][Full Text] [Related]
8. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
[TBL] [Abstract][Full Text] [Related]
9. Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla
Neuser J; Akin M; Bavendiek U; Kempf T; Bauersachs J; Widder JD
BMC Cardiovasc Disord; 2016 Nov; 16(1):217. PubMed ID: 27832757
[TBL] [Abstract][Full Text] [Related]
10. Transcatheter Closure of Patent Foramen Ovale: Randomized Trial Update.
Arfaras-Melainis A; Palaiodimos L; Mojadidi MK
Interv Cardiol Clin; 2019 Oct; 8(4):341-356. PubMed ID: 31445719
[TBL] [Abstract][Full Text] [Related]
11. Catheter closure of patent foramen ovale in patients with cryptogenic cerebrovascular accidents: initial experiences in Japan.
Kijima Y; Akagi T; Nakagawa K; Taniguchi M; Ueoka A; Deguchi K; Toh N; Oe H; Kusano K; Sano S; Ito H
Cardiovasc Interv Ther; 2014 Jan; 29(1):11-7. PubMed ID: 23824518
[TBL] [Abstract][Full Text] [Related]
12. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
Akobeng AK; Abdelgadir I; Boudjemline Y; Hijazi ZM
Catheter Cardiovasc Interv; 2018 Jul; 92(1):165-173. PubMed ID: 29602258
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
[TBL] [Abstract][Full Text] [Related]
14. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
[TBL] [Abstract][Full Text] [Related]
15. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
[TBL] [Abstract][Full Text] [Related]
16. The IrisFIT Patent Foramen Ovale Closure Device in Patients With History of Cryptogenic Embolization.
Hornung M; Bertog SC; Gafoor S; Reinartz M; Vaskelyte L; Hofmann I; Sievert K; Matic P; Grunwald I; Sievert H
J Invasive Cardiol; 2019 Nov; 31(11):319-324. PubMed ID: 31522140
[TBL] [Abstract][Full Text] [Related]
17. The role of device closure of patent foramen ovale in patients with cryptogenic stroke.
Fukutomi M; Wilkins B; Søndergaard L
J Intern Med; 2020 Oct; 288(4):400-409. PubMed ID: 32812297
[TBL] [Abstract][Full Text] [Related]
18. Patent foramen ovale--assessment and treatment.
Irwin B; Ray S
Cardiovasc Ther; 2012 Jun; 30(3):e128-35. PubMed ID: 21883994
[TBL] [Abstract][Full Text] [Related]
19. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence.
Mir H; Siemieniuk RAC; Ge L; Foroutan F; Fralick M; Syed T; Lopes LC; Kuijpers T; Mas JL; Vandvik PO; Agoritsas T; Guyatt GH
BMJ Open; 2018 Jul; 8(7):e023761. PubMed ID: 30049703
[TBL] [Abstract][Full Text] [Related]
20. Device Closure of Patent Foramen Ovale for Cryptogenic Stroke: Patient Selection and Outcomes According to New Randomized Trials.
Carroll AM; Carroll JD
Curr Cardiol Rep; 2019 Apr; 21(6):48. PubMed ID: 31011896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
